IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Clinical trial NCT05742607 · RECRUITING
Trial details
- NCT number
- NCT05742607
- Sponsor
- Innate Pharma
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-23
- Primary completion
- 2027-06-01
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.